Zai Lab Limited - ADR logo

ZLAB

Zai Lab Limited - ADR

$42.05

Earnings Summary

Revenue
$46.72Mn
Net Profits
$-82.39Mn
Net Profit Margins
-176.34%

Highlights

Revenue:

Zai Lab Limited - ADR’s revenue jumped 132.42% since last year same period to $46.72Mn in the Q1 2022. On a quarterly growth basis, Zai Lab Limited - ADR has generated 5.78% jump in its revenue since last 3-months.

Net Profits:

Zai Lab Limited - ADR’s net profit jumped 64.62% since last year same period to $-82.39Mn in the Q1 2022. On a quarterly growth basis, Zai Lab Limited - ADR has generated 61.1% jump in its net profits since last 3-months.

Net Profit Margins:

Zai Lab Limited - ADR’s net profit margin jumped 84.78% since last year same period to -176.34% in the Q1 2022. On a quarterly growth basis, Zai Lab Limited - ADR has generated 63.23% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zai Lab Limited - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-1.2
EPS Estimate Current Year
-1.2

Highlights

EPS Estimate Current Quarter:

Zai Lab Limited - ADR’s earning per share (EPS) estimates for the current quarter stand at -1.2 - a 9.77% jump from last quarter’s estimates.

EPS Estimate Current Year:

Zai Lab Limited - ADR’s earning per share (EPS) estimates for the current year stand at -1.2.

Key Ratios

Key ratios of the Zai Lab Limited - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-0.86
Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-0.55
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Zai Lab Limited - ADR’s earning per share (EPS) jumped 67.34% since last year same period to -0.86 in the Q1 2022. This indicates that the Zai Lab Limited - ADR has generated 67.34% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zai Lab Limited - ADR’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zai Lab Limited - ADR’s return on equity (ROE) stands at -0.55.

Dividend Per Share (DPS):

Zai Lab Limited - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-1.2
-0.86
28.14%

Company Information

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

Organisation
Zai Lab Limited - ADR
Headquarters
Shanghai, Shanghai, China (Mainland)
Employees
2.02K
Industry
Health Technology